Dr. Reddy`s Laboratories Ltd

Research Dr. Reddy`s Laboratories Ltd (RDY) on Bullrun: valuation model: 15.0% undervalued, market cap USD 12.37B, P/E 25.3, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRDY
• ExchangeNYSE
• CountryIndia
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal15.0% undervalued
• Market capUSD 12.37B
• P/E25.3
• Dividend yield0.6%
• Financial periodQ1 2026
• RevenueUSD 75.16B
• Net incomeUSD 41.96B
• Free cash flowUSD 18.33B
• Gross margin284.1%

Valuation Snapshot

Bullrun's latest valuation model marks Dr. Reddy`s Laboratories Ltd as 15.0% undervalued; latest market cap is USD 12.37B; P/E is 25.3; dividend yield is 0.6%.

About Dr. Reddy`s Laboratories Ltd

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.

Frequently asked questions

Is Dr. Reddy`s Laboratories Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Dr. Reddy`s Laboratories Ltd as 15.0% undervalued.

What is Dr. Reddy`s Laboratories Ltd's market cap?

Dr. Reddy`s Laboratories Ltd's market capitalization is USD 12.37B.

What is Dr. Reddy`s Laboratories Ltd's P/E ratio?

Dr. Reddy`s Laboratories Ltd's price-to-earnings (P/E) ratio is 25.3.

Does Dr. Reddy`s Laboratories Ltd pay a dividend?

Dr. Reddy`s Laboratories Ltd has a dividend yield of 0.6%.

What does Dr. Reddy`s Laboratories Ltd do?

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.